Revenue and Sales Performance - Revenue for the three months ended March 31, 2025, was $61.3 million, a slight increase of $0.2 million or 0.3% compared to $61.1 million for the same period in 2024[109] - Sales of airway clearance products increased by $1.9 million, or 22%, to $10.7 million, while lymphedema product sales decreased by $1.8 million, or 3%, to $50.6 million[113] - The AffloVest product line accounted for 17% of total revenue in the three months ended March 31, 2025, up from 14% in the same period in 2024[101] Profitability and Expenses - Gross margin improved to 74% for the three months ended March 31, 2025, compared to 71% for the same period in 2024[116] - Operating expenses rose by $3.5 million, or 8%, to $49.9 million, driven primarily by a $3.7 million increase in reimbursement, general, and administrative expenses[112] - Net loss for the three months ended March 31, 2025, was $3.0 million, compared to a net loss of $2.2 million for the same period in 2024, reflecting a 35% increase in losses[109] Research and Development - Research and development expenses decreased by $0.4 million, or 19%, to $1.7 million, primarily due to lower clinical study-related expenses[119] - The company launched the Entre Plus system in March 2024 and the Nimbl platform for lymphedema in October 2024, indicating ongoing product development[100] Financial Position and Cash Flow - As of March 31, 2025, the company had cash of $83.6 million and net accounts receivable of $35.7 million, compared to cash of $60.7 million and net accounts receivable of $47.4 million at March 31, 2024[124] - Net cash provided by operating activities was $0.4 million for the three months ended March 31, 2025, down from $0.9 million for the same period in 2024[125][126] - Net cash used in investing activities was $0.4 million for the three months ended March 31, 2025, compared to $0.5 million for the same period in 2024[127] - Net cash used in financing activities was $10.8 million for the three months ended March 31, 2025, primarily due to $10.0 million for the repurchase of common stock[128] - The company repurchased 635,603 shares for approximately $10.0 million during the three months ended March 31, 2025, with approximately $16.5 million remaining authorized under the stock repurchase program[140] Debt and Tax - As of March 31, 2025, the company had outstanding borrowings of $25.5 million under the Credit Agreement, with a required quarterly repayment of $750,000[137] - The company recorded an income tax benefit of $1.1 million for the three months ended March 31, 2025, up from $0.6 million in the same period in 2024[123] Interest Income and Expense - Interest income increased by $0.2 million, or 26%, to $0.9 million for the three months ended March 31, 2025, compared to $0.7 million for the same period in 2024[122] - Interest expense decreased by $0.2 million, or 25%, to $0.4 million for the three months ended March 31, 2025, compared to $0.6 million for the same period in 2024[122] Strategic Investments - The company continues to invest in its commercial infrastructure, including a direct sales force and reimbursement capabilities, to support growth[102] - The company estimates potential impacts of tariffs on its cost of goods sold could be up to $5.0 million for the year ended December 31, 2025[145] Workforce - The company employed 161 account managers and 103 specialists for lymphedema products as of March 31, 2025, compared to 158 account managers and 111 specialists a year earlier[104]

Revenue Performance - Total revenue for Q1 2025 increased by $180 thousand, or 0.3%, to $61.3 million compared to Q1 2024[4] - Total revenue for Q1 2025 was $61,268,000, a slight increase of 0.3% compared to $61,088,000 in Q1 2024[24] - Sales revenue decreased to $52,469,000 in Q1 2025 from $53,307,000 in Q1 2024, representing a decline of 1.6%[24] - Rental revenue increased to $8,799,000 in Q1 2025, up 13.1% from $7,781,000 in Q1 2024[24] - Lymphedema products accounted for 83% of total revenue in Q1 2025, down from 86% in Q1 2024[27] - The company expects full year 2025 total revenue in the range of $309 million to $315 million, representing growth of approximately 5% to 8% year-over-year[11] Profitability - Gross profit for Q1 2025 increased by $1.9 million, or 4%, to $45.3 million, with a gross margin of 74% compared to 71% in Q1 2024[5] - Gross profit for Q1 2025 was $45,346,000, an increase of 4.4% compared to $43,429,000 in Q1 2024[24] - Adjusted EBITDA loss for Q1 2025 was $0.3 million, compared to positive Adjusted EBITDA of $1.0 million in Q1 2024[9] - Adjusted EBITDA for Q1 2025 was $(259,000), a decrease of 125% from $1,033,000 in Q1 2024[28] - The company now expects full year 2025 adjusted EBITDA in the range of $32 million to $34 million, compared to adjusted EBITDA of $37.1 million in 2024[12] Expenses and Losses - Net loss for Q1 2025 was $3.0 million, or $(0.13) per diluted share, compared to a net loss of $2.2 million, or $(0.09) per diluted share, in Q1 2024[8] - Net loss for Q1 2025 was $2,974,000, compared to a net loss of $2,209,000 in Q1 2024, reflecting a 34.7% increase in losses[24] - Operating expenses increased by $3.5 million, or 8%, to $49.9 million, primarily due to planned strategic investments[7] - Operating expenses rose to $49,888,000 in Q1 2025, up 7.4% from $46,393,000 in Q1 2024[24] Cash and Stock Repurchase - As of March 31, 2025, the company had $83.6 million in cash and $25.5 million of outstanding borrowings under its credit agreement[10] - Cash at the end of Q1 2025 was $83,619,000, a decrease from $94,367,000 at the beginning of the period[26] - The company repurchased $10.0 million of stock during Q1 2025 under its share repurchase program[6]

Core Insights - Tactile Systems Technology, Inc. reported a total revenue increase of 0.3% year-over-year to $61.3 million for Q1 2025, driven by a 22% increase in airway clearance product sales, while lymphedema product sales decreased by 3% [4][9][12] - The company is focused on strategic growth initiatives, including the launch of Nimbl for lower extremity lymphedema and optimization of its sales organization [3][4] - The net loss for Q1 2025 was $3.0 million, compared to a net loss of $2.2 million in Q1 2024, reflecting ongoing investments in strategic initiatives [7][10] Financial Performance - Gross profit increased by 4% to $45.3 million, with a gross margin of 74%, up from 71% in Q1 2024, primarily due to lower manufacturing and warranty costs [5][9] - Operating expenses rose by 8% to $49.9 million, attributed to planned strategic investments, resulting in an operating loss of $4.5 million [6][9] - Adjusted EBITDA loss was $0.3 million in Q1 2025, compared to a positive Adjusted EBITDA of $1.0 million in Q1 2024 [10][9] Balance Sheet and Cash Flow - As of March 31, 2025, the company had $83.6 million in cash and $25.5 million in outstanding borrowings, down from $94.4 million in cash at the end of 2024 [11] - The company repurchased $10.0 million of its stock during the first quarter, with $16.5 million remaining under its share repurchase program [11][9] 2025 Financial Outlook - The company updated its 2025 revenue guidance to a range of $309 million to $315 million, representing a growth of approximately 5% to 8% year-over-year [12] - Adjusted EBITDA for 2025 is now expected to be in the range of $32 million to $34 million, down from previous expectations of $35 million to $37 million [13]

Core Viewpoint - Tactile Systems Technology, Inc. is set to release its first quarter fiscal year 2025 financial results on May 5, 2025, after market close, indicating ongoing developments in the medical technology sector focused on chronic disorders [1]. Financial Results Announcement - The financial results for the first quarter of fiscal year 2025 will be announced after the market closes on May 5, 2025 [1]. - A conference call will be held at 5:00 p.m. Eastern Time on the same day to discuss the results, with participation details provided [2]. Conference Call Details - Participants can join the conference call by dialing 877-407-3088 (international callers: 201-389-0927) and using access code 13752588 [2]. - A live webcast of the call will be available on the investor relations section of the company's website [2]. Replay Information - For those unable to attend the live call, a replay will be available for two weeks at 877-660-6853 (international callers: 201-612-7415) with the same access code [3]. - The webcast will also be archived on the company's investor relations website [3]. Company Overview - Tactile Medical specializes in developing and marketing at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease [4]. - The company collaborates with clinicians to enhance clinical evidence, raise awareness, improve access to care, reduce healthcare costs, and enhance the quality of life for patients [4].

MINNEAPOLIS, March 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. ("Tactile Medical"; the "Company") (NASDAQ:TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference, which is being virtually held from March 17th – 20th. Management will participate in a virtual presentation on Tuesday, March 18th at 12:00 p.m. Eastern Time. A live audio web ...

Core Insights - Tactile Systems Technology, Inc. will participate in the Oppenheimer 35th Annual Healthcare MedTech & Services Conference virtually from March 17 – 20, with a presentation scheduled for March 18 at 12:00 p.m. Eastern Time [1] - A live audio webcast of the presentation will be available on the company's investor relations website, with an archive for replay after the conference [2] - Tactile Medical specializes in at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease, aiming to improve patient quality of life and reduce healthcare costs [3]

Tactile Systems Technology, Inc. (NASDAQ:TCMD) Q4 2024 Earnings Conference Call February 18, 2025 5:00 PM ET Company Participants Sam Bentzinger - Investor Relations, Gilmartin Group LLC Sheri Dodd - Chief Executive Officer Elaine Birkemeyer - Chief Financial Officer Conference Call Participants Max Smock - William Blair Adam Maeder - Piper Sandler Iseult McMahon - BTIG Kyle Bauser - B. Riley Securities Suraj Kalia - Oppenheimer & Company Operator Please standby. Welcome, ladies and gentlemen, to the Fourth ...

Financial Results Announcement - Tactile Systems Technology, Inc. will release its fourth quarter and fiscal year 2024 financial results after market close on February 18, 2025 [1] - A conference call will be held at 5:00 p.m. Eastern Time on the same day to discuss the results [2] Conference Call Details - Participants can join the call by dialing 877-407-3088 (international callers: 201-389-0927) and using access code 13751026 [2] - A live webcast will be available on the investor relations section of the Company's website [2] Replay Information - A replay of the conference call will be accessible for two weeks at 877-660-6853 (international callers: 201-612-7415) with the same access code [3] - The webcast will be archived on the Company's investor relations website [3] Company Overview - Tactile Medical specializes in developing and marketing at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease [4] - The Company aims to improve the quality of life for patients by collaborating with clinicians to enhance clinical evidence and increase access to care [4]

Core Insights - Tactile Systems Technology, Inc. has launched its next-generation pneumatic compression platform, Nimbl, for both upper and lower extremity lymphedema treatment, expanding its availability across the U.S. [1][2] Product Features - Nimbl is the smallest pneumatic compression device of its kind, featuring a controller that is 68% lighter and 40% smaller than the previous generation [2] - The lower extremity garment uses 94% less hosing, enhancing transportability and ease of management [2] - Nimbl is the only basic pneumatic compression device with Bluetooth connectivity, allowing patients to track treatments and symptom progress via the Kylee™ digital application [2] Patient-Centric Design - The device is designed to be user-friendly and comfortable, promoting increased adherence to treatment [3] - Its compact design and reduced hose length facilitate easier transport within the home and during travel, improving the overall patient experience [3] Company Overview - Tactile Medical focuses on developing at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease [4] - The company collaborates with clinicians to enhance clinical evidence, raise awareness, and improve patient care while reducing healthcare costs [4]

Company Overview - Tactile Systems Technology, Inc. (Tactile Medical) is a medical technology company focused on providing therapies for individuals with chronic disorders, particularly underserved conditions such as lymphedema, lipedema, chronic venous insufficiency, and chronic pulmonary disease [3]. Leadership Appointment - Laura King has been appointed to the Board of Directors of Tactile Medical and will also serve on the Audit and Compliance & Reimbursement Committees, effective January 13, 2025 [1]. - Ms. King brings over 22 years of experience from General Electric Company (GE), where she held various senior roles, including President & CEO of GE Healthcare's Global Interventional Business [2]. - Her previous leadership roles include co-founding BiaCure, Inc. and Elucent Medical, and serving as President & CEO of NeuWave Medical, which was acquired by Johnson & Johnson's MedTech division [2]. Strategic Impact - The appointment of Laura King is expected to enhance Tactile Medical's capabilities in developing innovative technologies aimed at improving patient care, particularly in the areas of lymphedema and airway clearance therapies [2]. - The company collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce healthcare costs, and improve the quality of life for patients [3].